Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

3D printing is a manufacturing game-changer

Calling all carnivores: ever thought about getting a meat printer? Of hand-crafting delectable beef steaks at home from plant proteins, that have the same texture, appearance and flavor as real meat, only without the distasteful killing part? 3D-printed steaks and chicken ...
Richard (Rick) Mills | November 15, 2019 |

Rare Diseases Biotech Provides Opportunity

A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. In a March 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi indicated that the recent drop in Soleno Therapeutics Inc.'s (SL...
Streetwise Reports | March 22, 2019 |

The Logic Behind Buying Gold Now

Rudi Fronk and Jim Anthony, co-founders of Seabridge Gold, discuss Fed policies and what they mean for gold. In our view, the gold story is getting much simpler and much more urgent. Here is how we see it. The Fed cannot exit QE. QE is a failed policy. More QE is comi...
Streetwise Reports | March 26, 2019 |

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device in FDA Approval Process

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. You don't often hear about it, but bladder cancer is the sixth most common cancer in the U.S., with approximately 80,000 cases reported every year, and some 600,000 Americans living in ...
Streetwise Reports | November 13, 2019 |

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. Imagin Medical's disruptive technology is poised to deliver the most significant advancement in bladder cancer detection and removal in decades , ma...
Streetwise Reports | January 15, 2020 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

SunPower (SPWRA): Retreating into familiar territory

Last week, SunPower Corporation ( NASDAQ: SPWRA , Stock Forum ) updated its 2011 guidance, predicting that ex-items earnings per share would range between $1.75 and $2.05. Revenue for the upcoming fiscal year is predicted to arrive between $2.65 billion and $2.85 billion....
Andrea Kramer | October 28, 2012 |
1 2 3 4 5 6 7